Basic Information


GTO ID GTC0345
Trial ID NCT02992210
Disease Solid Tumor
Altered gene GD2
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment GD2 CAR-T cells
Generation4th
PhasePhase1|Phase2
Recruitment statusUnknown
TitleStudy on GD2 Positive Solid Tumors by 4SCAR-GD2
Year2016
CountryChina
Company sponsorShenzhen Geno-Immune Medical Institute
Other ID(s)GIMI-IRB-16002
Vector information
Vectorlentivirus
ConstructscFv-CD28-CD27-CD3ζ
Vector typeNHP/TYF lentivector system
Additional featureiCasp9

Clinical Result

Cohort 1
Administration route infusion
Dosage 1.1E6 cells/kg, average dose
Donor type Autologous
Pts 34
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 5/34(PR); 13/34(SD); 16/34(PD). The 1-year overall survival rate is 74%.
Adverse reactions no any CAR-T-related severe events
References DOI: 10.1182/blood-2022-164461

Relationship Graph

Overview of Knowledge Graph